KFDA criticized for anti-obesity medicine license

Published: 2006-10-25 07:00:00

Updated: 2006-10-25 07:00:00

A lawmaker took issue with the Korea Food and Drug Administration's license withdrawal of Hanmi Pharm's anti-obesity drug Slimmer in the annual parliamentary audit on October 23, criticizing the health regulator's lack of equity in the procedures of drug approval.

Slimmer was a modified salt of Reductil (sibutramine) developed by Abbott, the U.S. based pharmaceutical firm.

Hanmi Pharm sub...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.